Docoh
Loading...

FMTX Forma Therapeutics

News

From Benzinga Pro
SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Lowers Price Target to $40
12 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Andrew Berens maintains Forma Therapeutics Hldgs (NASDAQ:FMTX) with a Outperform and lowers the price target from $54 to $40.
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
12 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Forma Therapeutics Hldgs Q3 EPS $(0.91) Beats $(0.96) Estimate
12 Nov 21
Earnings, News
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(0.96) by 5.21 percent. This is a 35.82 percent decrease over losses of $(0.67) per
Earnings Scheduled For November 12, 2021
12 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11)
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
45 Biggest Movers From Yesterday
8 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
'Re: $FMTX today, there's a precedent for an experimental cancer drug being linked to potential diabetes risk. Who remembers $CLVS, roci and the 2014 ASCO meeting...' -Tweet From STAT News' Adam Feuerstein
7 Oct 21
Analyst Color, Biotech, News, FDA, Analyst Ratings, General
https://twitter.com/adamfeuerstein/status/1446125329915912192
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
Forma Therapeutics' FT-7051 Is Well-tolerated And Demonstrates Evidence If Activity In Initial Results From Ongoing Phase 1 Courage Study In Men With Metastatic Castration-resistant Prostate Cancer
7 Oct 21
Biotech, News, FDA, General
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced positive
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
3 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.

Press releases

From Benzinga Pro
Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
30 Nov 21
Press Releases
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the appointment of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 Nov 21
Press Releases
Significant progress achieved on three clinical stage programs focused on rare hematologic diseases and cancers Etavopivat Phase 1 open label extension enrollment in sickle cell disease (SCD) complete, updated results
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
5 Nov 21
Press Releases
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced that it
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
4 Nov 21
Press Releases
Two oral presentations on etavopivat include data from Forma's Phase 1 open label extension trial in sickle cell disease demonstrating a favorable tolerability profile consistent with previously-reported results
Mission BioCapital Announces $275 Million Fund V
4 Nov 21
Press Releases
Record new fund to help biopharma startups achieve pivotal early stage growth Mission BioCapital, a venture capital firm focused on making investments in early-stage life sciences companies that it uniquely supports as
Forma Therapeutics' FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
7 Oct 21
Press Releases
Initial eight patients treated in ongoing first-in-human, open-label, dose-finding trial of CBP/p300 inhibitor in late-line mCRPC patients Adaptive trial design intended to efficiently explore safe and efficacious
Forma Therapeutics to Participate in Upcoming Investor Conferences
17 Sep 21
Press Releases
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in two upcoming